These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18622250)

  • 1. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
    MacDonald TM; Reginster JY; Littlejohn TW; Richard D; Lheritier K; Krammer G; Rebuli R
    J Hypertens; 2008 Aug; 26(8):1695-702. PubMed ID: 18622250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents.
    MacDonald TM; Richard D; Lheritier K; Krammer G
    Int J Clin Pract; 2010 May; 64(6):746-55. PubMed ID: 20518950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen.
    Farkouh ME; Verheugt FW; Ruland S; Kirshner H; Jeger R; Gitton X; Krammer G; Stricker K; Sallstig P; Mellein B; Matchaba P; Chesebro JH
    J Clin Hypertens (Greenwich); 2008 Aug; 10(8):592-602. PubMed ID: 18772641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
    Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
    Hawkey CJ; Weinstein WM; Smalley W; Gitton X; Sallstig P; Stricker K; Krammer G; Mellein B; Richard D; Matchaba P
    Gastroenterology; 2007 Jul; 133(1):57-64. PubMed ID: 17631131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis.
    Kivitz AJ; Nayiager S; Schimansky T; Gimona A; Thurston HJ; Hawkey C
    Aliment Pharmacol Ther; 2004 Jun; 19(11):1189-98. PubMed ID: 15153172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients.
    Stricker K; Yu S; Krammer G
    BMC Musculoskelet Disord; 2008 Sep; 9():118. PubMed ID: 18778469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
    Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial.
    Ruschitzka F; Borer JS; Krum H; Flammer AJ; Yeomans ND; Libby P; Lüscher TF; Solomon DH; Husni ME; Graham DY; Davey DA; Wisniewski LM; Menon V; Fayyad R; Beckerman B; Iorga D; Lincoff AM; Nissen SE
    Eur Heart J; 2017 Nov; 38(44):3282-3292. PubMed ID: 29020251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.
    Whelton A; Lefkowith JL; West CR; Verburg KM
    Kidney Int; 2006 Oct; 70(8):1495-502. PubMed ID: 16941030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
    Hawkey CC; Svoboda P; Fiedorowicz-Fabrycy IF; Nasonov EL; Pikhlak EG; Cousin M; Gitton X; Hoexter G
    J Rheumatol; 2004 Sep; 31(9):1804-10. PubMed ID: 15338504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
    Hawkey CJ; Farkouh M; Gitton X; Ehrsam E; Huels J; Richardson P
    Aliment Pharmacol Ther; 2004 Jul; 20(1):51-63. PubMed ID: 15225171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
    Fleischmann R; Tannenbaum H; Patel NP; Notter M; Sallstig P; Reginster JY
    BMC Musculoskelet Disord; 2008 Mar; 9():32. PubMed ID: 18328090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.
    Bannwarth B; Berenbaum F
    Expert Opin Investig Drugs; 2005 Apr; 14(4):521-33. PubMed ID: 15882125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
    Daniels S; Gitton X; Zhou W; Stricker K; Barton S
    J Womens Health (Larchmt); 2008 Apr; 17(3):423-37. PubMed ID: 18373490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
    Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
    Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
    Hawkey CJ; Gitton X; Hoexter G; Richard D; Weinstein WM
    Clin Gastroenterol Hepatol; 2006 Jan; 4(1):57-66. PubMed ID: 16431306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.